The mRNA expression of inhibitors of DNA binding-1 and -2 is associated with advanced tumour stage and adverse clinical outcome in human breast cancer

Anticancer Research

Volumn 33, Issue 5, 2013, Pages 2179-2184

  Wazir, Umar ^a,b   Jiang, Wen G ^c   Sharma, Anup K ^b   Newbold, Robert F ^a   Mokbel, Kefah ^a,b  

^a Princess Grace Hospital   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Breast cancer; Cell cycle; Helix loop helix; ID1; ID2; Inhibitor of differentiation; Inhibitor of DNA binding; qPCR

Indexed keywords

INHIBITOR OF DIFFERENTIATION 1; INHIBITOR OF DIFFERENTIATION 2; MESSENGER RNA;

ADVERSE OUTCOME; ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CANCER TISSUE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; HUMAN; HUMAN TISSUE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BREAST CANCER; CELL CYCLE; HELIX-LOOP-HELIX; ID1; ID2; INHIBITOR OF DIFFERENTIATION; INHIBITOR OF DNA BINDING; QPCR;

ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; BREAST; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CARCINOMA, MEDULLARY; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; INHIBITOR OF DIFFERENTIATION PROTEIN 1; INHIBITOR OF DIFFERENTIATION PROTEIN 2; INHIBITOR OF DIFFERENTIATION PROTEINS; NEOPLASM GRADING; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84878170965     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Hasskarl J and Munger K: ID proteins-tumor markers or oncogenes? Cancer Biol Ther 1: 91-96, 2002.
2. Benezra R, Davis RL, Lockshon D, Turner DL and Weintraub H: The protein ID: A negative regulator of helix-loop-helix DNA-binding proteins. Cell 61: 49-59, 1990.
3. Al Sarakbi W, Sasi W, Jiang WG, Roberts T, Newbold RF and Mokbel K: The mRNA expression of SETD2 in human breast cancer: correlation with clinico-pathological parameters. BMC Cancer 9: 290, 2009.
4. Elkak A, Mokbel R, Wilson C, Jiang WG, Newbold RF and Mokbel K: hTERT mRNA expression is associated with a poor clinical outcome in human breast cancer. Anticancer Res 26: 4901-4904, 2006. (Pubitemid 46032131)
5. Wazir U, Jiang WG, Sharma AK and Mokbel K: The mRNA expression of DAP3 in human breast cancer: Correlation with clinicopathological parameters. Anticancer Res 32: 671-674, 2012.
6. Jiang WG, Watkins G, Lane J, Cunnick GH, Douglas-Jones A, Mokbel K and Mansel RE: Prognostic value of rho GTPases and rho guanine nucleotide dissociation inhibitors in human breast cancers. Clin Cancer Res 9: 6432-6440, 2003. (Pubitemid 38031830)
7. Massari ME and Murre C: Helix-loop-helix proteins: Regulators of transcription in eucaryotic organisms. Mol Cell Biol 20: 429-440, 2000. (Pubitemid 30023084)
8. Riechmann V, van Cruchten I and Sablitzky F: The expression pattern of ID4, a novel dominant negative helix-loop-helix protein, is distinct from ID1, ID2 and ID3. Nucleic Acids Res 22: 749-755, 1994. (Pubitemid 24160899)
9. O'Brien CA, Kreso A, Ryan P, Hermans KG, Gibson L, Wang Y, Tsatsanis A, Gallinger S and Dick JE: ID1 and ID3 regulate the self-renewal capacity of human colon cancer-initiating cells through p21. Cancer Cell 21: 777-792, 2012.
10. Pillai S, Rizwani W, Li X, Rawal B, Nair S, Schell MJ, Bepler G, Haura E, Coppola D and Chellappan S: ID1 facilitates the growth and metastasis of non-small cell lung cancer in response to nicotinic acetylcholine receptor and epidermal growth factor receptor signaling. Mol Cell Biol 31: 3052-3067, 2011.
11. Lin CQ, Singh J, Murata K, Itahana Y, Parrinello S, Liang SH, Gillett CE, Campisi J and Desprez PY: A role for ID1 in the aggressive phenotype and steroid hormone response of human breast cancer cells. Cancer Res 60: 1332-1340, 2000. (Pubitemid 30152003)
12. Shuno Y, Tsuno NH, Okaji Y, Tsuchiya T, Sakurai D, Nishikawa T, Yoshikawa N, Sasaki K, Hongo K, Tsurita G, Sunami E, Kitayama J, Tokunaga K, Takahashi K and Nagawa H: ID1/ID3 knockdown inhibits metastatic potential of pancreatic cancer. J Surg Res 161: 76-82, 2010.
13. Tobin NP, Sims AH, Lundgren KL, Lehn S and Landberg G: Cyclin D1, ID1 and EMT in breast cancer. BMC Cancer 11: 417, 2011.
14. Lasorella A, Iavarone A and Israel MA: ID2 specifically alters regulation of the cell cycle by tumor suppressor proteins. Mol Cell Biol 16: 2570-2578, 1996. (Pubitemid 26161260)
15. Stighall M, Manetopoulos C, Axelson H and Landberg G: High ID2 protein expression correlates with a favourable prognosis in patients with primary breast cancer and reduces cellular invasiveness of breast cancer cells. Int J Cancer 115: 403-411, 2005. (Pubitemid 40663744)
16. Itahana Y, Singh J, Sumida T, Coppe JP, Parrinello S, Bennington JL and Desprez PY: Role of ID2 in the maintenance of a differentiated and noninvasive phenotype in breast cancer cells. Cancer Res 63: 7098-7105, 2003. (Pubitemid 37413446)
17. Rollin J, Blechet C, Regina S, Tenenhaus A, Guyetant S and Gidrol X: The intracellular localization of ID2 expression has a predictive value in non-small cell lung cancer. PLoS ONE 4: e4158, 2009.
18. Meng Y, Gu C, Wu Z, Zhao Y, Si Y, Fu X and Han W: ID2 promotes the invasive growth of MCF-7 and SKOV-3 cells by a novel mechanism independent of dimerization to basic helix-loop- helix factors. BMC Cancer 9: 75, 2009.
19. Senst C, Nazari-Shafti T, Kruger S, Bentrup KH, Dupin CL, Chaffin AE, Srivastav SK, Worner PM, Abdel-Mageed AB, Alt EU and Izadpanah R: Prospective dual role of mesenchymal stem cells in breast tumor microenvironment. Breast Cancer Res Treat 137: 69-79, 2013.
20. Wicha MS: Migratory gene expression signature predicts poor patient outcome: Are cancer stem cells to blame? Breast Cancer Res 14: 114-114, 2012.